<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02752815</url>
  </required_header>
  <id_info>
    <org_study_id>NHL-006</org_study_id>
    <nct_id>NCT02752815</nct_id>
  </id_info>
  <brief_title>Reduced Chemotherapy in Low Risk DLBCL</brief_title>
  <official_title>Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial to compare the efficacy and safety of four cycles of R-CHOP followed
      by four cycles of Rituximab with six cycles of R-CHOP followed by two cycles of Rituximab in
      the treatment of de novo, low-risk, non-bulky diffuse large B-cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response rate</measure>
    <time_frame>21 days after 8 cycles of treatment（each cycle is 21 days）</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>Each cycle of treatment（each cycle is 21 days）and then every 3 months for 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>6R-CHOP+2R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 cycles of R-CHOP Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Epirubicin 70mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2－6 Frequency 21days
2 cycles of Rituximab monotherapy Rituximab 375 mg/m2 IV d1 Frequency 21days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4R-CHOP+4R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles of R-CHOP Rituximab 375 mg/m2 IV d1 Cyclophosphamide 750mg/m2 IV d2 Epirubicin 70mg/m2 IV d2 Vincristine 1.4 mg/m2 IV d2 Prednisone 60 mg/m2 PO d2－6 Frequency 21days
2 cycles of Rituximab monotherapy Rituximab 375 mg/m2 IV d1 Frequency 21days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>6R-CHOP+2R</arm_group_label>
    <arm_group_label>4R-CHOP+4R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>6R-CHOP+2R</arm_group_label>
    <arm_group_label>4R-CHOP+4R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <arm_group_label>6R-CHOP+2R</arm_group_label>
    <arm_group_label>4R-CHOP+4R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <arm_group_label>6R-CHOP+2R</arm_group_label>
    <arm_group_label>4R-CHOP+4R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>6R-CHOP+2R</arm_group_label>
    <arm_group_label>4R-CHOP+4R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed de novo diffuse large B-cell lymphoma, complete response
             after 4 cycles of standard R-CHOP21

          -  Age&gt;=14 y.o.,&lt;=75 y.o.

          -  IPI=0-1

          -  non-bulky (largest diameter &lt;7.5cm)

          -  ECOG =0-1

          -  Life expectancy&gt;6 months

          -  Informed consented

        Exclusion Criteria:

          -  Chemotherapy before

          -  Stem cell transplantation before

          -  History of malignancy, except for basal cell or squamous cell carcinoma of the skin or
             carcinoma in situ of the cervix

          -  Uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious
             disease

          -  Primary cutaneous, CNS DLBCL

          -  LVEF≤50%

          -  Other uncontrollable medical condition that may that may interfere the participation
             of the study

          -  Lab at enrollment(unless caused by lymphoma) Neutrophile&lt;1.5*10^9/L Platelet&lt;80*10^9/L
             Hemoglobulin&lt;100g/L ALT or AST &gt;2*ULN,AKP or bilirubin &gt;1.5*ULN Creatinine&gt;1.5*ULN

          -  Not able to comply to the protocol for mental or other unknown reasons

          -  Pregnant or lactation

          -  If HbsAg positive, should check HBV DNA, DNA positive patients cannot be enrolled. If
             HBsAg negative but HBcAb positive (whatever HBsAb status), should check HBV DNA,DNA
             positive patients cannot be enrolled.

          -  HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weili Zhao, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weili Zhao, MD, PhD</last_name>
    <phone>64370045</phone>
    <phone_ext>610707</phone_ext>
    <email>zhao.weili@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pengpeng Zhao, MD</last_name>
    <phone>64370045</phone>
    <phone_ext>610707</phone_ext>
    <email>xpproc@msn.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200023</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weili Zhao, MD,PhD</last_name>
      <phone>64370045</phone>
      <phone_ext>610707</phone_ext>
      <email>zhao.weili@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Pengpeng Xu, MD</last_name>
      <phone>64370045</phone>
      <phone_ext>610707</phone_ext>
      <email>xpproc@msn.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2016</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Weili</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

